Drugs / Valiloxybate
Valiloxybate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04688580 | Nov 2020 → Dec 2021 | — | XWPharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05056194 | Nov 2021 → Nov 2022 | Parkinson disease, sleep-wake disorder | XWPharma | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-14 | XWPharma | Results XWPharma Announces Positive Results from Phase 1 Clinical Trials of XW10172, in Development as Once-Nightly Therapy for Sleep Disorders in Patients with Neurodegenerative Diseases xwpharma.com ↗
XWPharma Ltd. today announced that XW10172, an internally discovered, novel, patented conjugate of the GABAB agonist oxybate, demonstrated in Phase 1 clinical trials multiple features that support development for treatment for various sleep disorders. |
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Valiloxybate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05056194 ↗ |
| Known as | Valiloxibic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095201 ↗ |
| Known as | XW10172 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04688580 ↗ |
| Known as | XWL-008 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095201 ↗ |
| Modality | Small molecule | — CHEMBL5095201 ↗ |
| Route | Oral | “XW10172 Oral Formulations” NCT04688580 ↗ |